Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Stock Information for Cognition Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cognition Therapeutics Inc.

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
Life Sciences Investor Forum Agenda Announced for November 14th
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.